Stevens-Johnson syndrome and toxic epidermal necrolysis in children: A review of the experience with paediatric patients in a University Hospital

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 10, 2011, Pages 1153-1159

  Ferrandiz Pulido C ^a   Garcia Fernandez D ^a   Dominguez Sampedro P ^a   Garcia Patos V ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

children; cutaneous drug reaction; Lyell syndrome; paediatrics; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAMAZEPINE; CEFOTAXIME; CLARITHROMYCIN; CORTICOSTEROID; DEXAMETHASONE; DIPYRONE; EMOLLIENT AGENT; IBUPROFEN; IMMUNOGLOBULIN; ITRACONAZOLE; LAMOTRIGINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN G; PHENOBARBITAL; PHENYTOIN; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; SULFADIAZINE SILVER;

ADOLESCENT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; BLINDNESS; BODY SURFACE; BRONCHITIS; CHILD; CLINICAL ARTICLE; CORNEA ULCER; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG ERUPTION; EPILEPSY; EPIPHORA; FEMALE; GENITAL ULCER; HUMAN; HYPERPIGMENTATION; HYPERTRANSAMINASEMIA; HYPOPIGMENTATION; INFANT; INTENSIVE CARE; LENGTH OF STAY; MALE; MENINGITIS; MOUTH ULCER; MYCOPLASMA PNEUMONIA; PERSONALITY DISORDER; PHOTOPHOBIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SEPSIS; SHOCK; SKIN EXFOLIATION; STEVENS JOHNSON SYNDROME; TONGUE DISEASE; TOXIC EPIDERMAL NECROLYSIS; TRICHIASIS; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT INFECTION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME; SURVIVAL RATE;

EID: 80053042397     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03935.x     Document Type: Article

References (46)

1. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-253.
2. Roujeau JC,. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102: 28S-30S.
3. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
4. Forman R, Koren G, Shear NH,. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002; 25: 965-972.
5. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009; 123: 297-304.
6. Ruiz-Maldonado R,. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13: 623-635.
7. Prendiville JS, Hebert AA, Greenwald MJ, et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989; 115: 881-887.
8. Sheridan RL, Weber JM, Schulz JT, et al. Management of severe toxic epidermal necrolysis in children. J Burn Care Rehabil 1999; 20: 497-500.
9. Jones WG, Halebian P, Madden M, et al. Drug-induced toxic epidermal necrolysis in children. J Pediatr Surg 1989; 24: 167-170.
10. Taylor JA, Grube B, Heimbach DM, et al. Toxic epidermal necrolysis. A comprehensive approach. Multidisciplinary management in a burn center. Clin Pediatr 1989; 28: 404-407.
11. Spies M, Sanford AP, Aili Low JF, et al. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001; 108: 1162-1168.
12. Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47: 548-552.
13. Koh MJ, Tay YK,. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol 2010; 62: 54-60.
14. Halevy S, Ghislain PD, Mockenhaupt M, et al. EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
15. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome,and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49: 769-773.
16. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-47.
17. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
18. Roujeau JC, Chosidow O, Saiag P, et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-1058.
19. Abood GJ, Nickoloff BJ, Gamelli RL,. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008; 29: 269-276.
20. García-Fernández D, García-Patos Briones V, Castells Rodellas A,. Síndrome de Stevens/Johnson/necrõlisis epidérmica tõxica. Piel 2001; 16: 444-457.
21. Goyal S, Gupta P, Ryan CM, et al. Toxic epidermal necrolysis in children: medical, surgical, and ophthalmologic considerations. J Burn Care Res 2009; 30: 437-449.
22. Wolkenstein PE, Roujeau JC, Revuz J,. Drug-induced toxic epidermal necrolysis. Clin Dermatol 1998; 16: 399-408.
23. Guillaume JC, Roujeau JC, Revuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987; 123: 1166-1170.
24. Tay YK, Huff JC, Weston WL,. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996; 35: 757-760.
25. Teraki Y, Murota H, Izaki S,. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008; 144: 232-235.
26. Pereira FA, Mudgil AV, Rosmarin DM,. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181-200.
27. Laguna C, Martín B, Torrijos A, et al. Síndrome de Stevens-Johnson y necrõlisis epidérmica tõxica: experiencia clínica y revisiõn de la literatura especializada. Actas Dermosifiliogr 2006; 97: 177-185.
28. Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-512.
29. Murphy JT, Purdue GF, Hunt JL,. Toxic epidermal necrolysis. J Burn Care Rehabil 1997; 18: 417-420.
30. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23: 87-96.
31. Yarbrough DR 3rd,. Treatment of toxic epidermal necrolysis in a burn center. J S C Med Assoc 1997; 93: 347-350.
32. Freiman A, Borsuk D, Sasseville D,. Dermatologic emergencies. CMAJ 2005; 173: 1317-1319.
33. Hazin R, Ibrahimi OA, Hazin MI, et al. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med 2008; 40: 129-138.
34. Fromowitz JS, Ramos-Caro FA, Flowers FP,. University of Florida. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 2007; 46: 1092-1094.
35. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
36. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
37. Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007; 33: 452-459.
38. Lam NS, Yang YH, Wang LC, et al. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 2004; 37: 366-370.
39. Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol 2000; 27: 2494-2497.
40. Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 2005; 71: 398-400.
41. Koh MJ, Tay YK,. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr 2009; 21: 505-510.
42. Prins C, Kerdel FA, Padilla RS, et al. TEN-IVIG Study Group Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
43. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 2003; 139: 39-43.
44. Schulz JT, Sheridan RL, Ryan CM, et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21: 199-204.
45. Fritsch P,. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Eur J Dermatol 2008; 18: 216-217.
46. Fritsch PO, Sidoroff A,. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1: 349-360.